IMVT-1402 — Initial data
2026
Initial results from open label period 1 of potentially registrational trial in ACPA+ difficult-to-treat rheumatoid arthritisSource filing
ROIV biotech catalysts & pipeline
ROIVANT SCIENCES LTD · Data as of 2026-09-08
Upcoming catalysts
IMVT-1402 — Topline data
H2 2026
Immunovant expects to report topline data from the proof-of-concept trial of IMVT-1402 in CLE and provide an update on the potentially registrational program of IMVT-1402 in D2T RA in the second half of calendar year 2026.Source filing
LISRAYA™ (brepocitinib) — Topline data
H2 2026
Priovant expects the commercial launch of brepocitinib in DM by the end of September 2026 and topline data from the Phase 3 study in NIU and Phase 3 study in CS in the second half of calendar year 2026 and calendar year 2028, respectively.Source filing
mosliciguat — Topline data
H2 2026
Pulmovant expects to report topline data from the ongoing Phase 2 trial of mosliciguat in PH-ILD in the second half of calendar year 2026.Source filing
LISRAYA™ (brepocitinib) — Topline data
Late 2026
Cutaneous Sarcoidosis Ph3 Ongoing Cutaneous Sarcoidosis Potential sNDA Approval Late 2026Source filing
IMVT-1402 — Topline data
2027
In calendar year 2027, topline data are expected across potentially registrational trials of IMVT-1402 in GD and MG.Source filing
IMVT-1402 — Topline data
2028
In calendar year 2028, topline data are expected across potentially registrational trials of IMVT-1402 in CIDP and SjD.Source filing
LISRAYA™ (brepocitinib) — Topline data
2028
Priovant expects the commercial launch of brepocitinib in DM by the end of September 2026 and topline data from the Phase 3 study in NIU and Phase 3 study in CS in the second half of calendar year 2026 and calendar year 2028, respectively.Source filing